Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HCB101 + trastuzumab + pertuzumab + oxaliplatin + capecitabine
- Development stage
- Unknown
- Lead developer
- Harbour BioMed
- Modality
- Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination regimen consisting of HCB101 (a novel Fc-based anti-SIRPα-CD47 fusion protein), trastuzumab (a monoclonal antibody targeting HER2/ERBB2), pertuzumab (a monoclonal antibody targeting a different HER2/ERBB2 epitope), oxaliplatin (a platinum-based chemotherapy agent), and capecitabine (an orally administered antimetabolite prodrug of 5-fluorouracil). HCB101 is being investigated for its role in blocking the CD47-SIRPα axis to promote phagocytosis of tumor cells, complementing the antitumor activities of the monoclonal antibodies and chemotherapies. This regimen is being evaluated in advanced solid tumors, including HER2-positive cancers where synergistic action is hypothesized between immunotherapies and chemotherapeutics[1][5][9].
- Other names
- trastuzumabpertuzumaboxaliplatincapecitabine
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)CD47 (Cluster of Differentiation 47)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on HCB101 + trastuzumab + pertuzumab + oxaliplatin + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HCB101 + trastuzumab + pertuzumab + oxaliplatin + capecitabine.